Company intelligence / Profile preview

Vagustim

San Francisco, California, United Statesvagustim.io ↗

Ownership: Private
Development stage: Commercial

Overview

The company has developed the world’s first multi-purpose smart non-invasive vagus nerve stimulation device. Backed by over 30 clinical studies and used by leading institutions such as Harvard and Yale in research settings. Clinical results cited include improvements in stress reduction, sleep quality, relaxation, gut health/balance of the autonomic nervous system. The product has shipped to over 40 countries worldwide.

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

v1

Commercial

Indications: General wellness

1 more asset in the full pipeline.

Request access →

Partnerships

Prestigious academic collaborations with Harvard University and Yale University for research purposes.

Beyond the preview

Go deeper on Vagustim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vagustim.

Explore the full profile